Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. - Wikidata - wikimedia - TriplyDB

Regression of established tumors and metastases by potent vascular endothelial growth factor blockade.

Regression of established tumors and metastases by potent vascular endothelial growth factor blockade.

http://www.wikidata.org/entity/Q35146833

about

Antiangiogenesis cocktails - stirred or shaken?Aflibercept Assessment of a novel VEGF targeted agent using patient-derived tumor tissue xenograft models of colon carcinoma with lymphatic and hepatic metastases Roles of the endogenous VEGF receptors flt-1 and flk-1 in astroglial and vascular remodeling after brain injury The antiangiogenic effects of a vascular endothelial growth factor decoy receptor can be monitored in vivo using contrast-enhanced ultrasound imaging.Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy Directed endothelial cell morphogenesis in micropatterned gelatin methacrylate hydrogels.Extravascular CX3CR1+ cells extend intravascular dendritic processes into intact central nervous system vessel lumen.Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors.Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data.Characterization of a WiT49 cell line derived orthotopic model of Wilms tumor.Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth.The VEGF family in cancer and antibody-based strategies for their inhibition.Exploiting novel molecular targets in gastrointestinal cancers.Pro-apoptotic BIM is an essential initiator of physiological endothelial cell death independent of regulation by FOXO3.Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches DCE and DW-MRI monitoring of vascular disruption following VEGF-Trap treatment of a rat glioma model Rapid vascular regrowth in tumors after reversal of VEGF inhibition.Uniform overexpression and rapid accessibility of alpha5beta1 integrin on blood vessels in tumors Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.Tumor Vessel Development and Expansion in Ewing's Sarcoma: A Review of the Vasculogenesis Process and Clinical Trials with Vascular-Targeting Agents.Building a better Trap Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade Inhibition of cyclo-oxygenase 2 reduces tumor metastasis and inflammatory signaling during blockade of vascular endothelial growth factor.Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.Translating angiogenesis research into the clinic: the challenges ahead.Monitoring early tumor response to drug therapy with diffuse optical tomography.Inhibition of angiogenesis in cancer patients.Therapeutic targeting of receptor tyrosine kinases in lung cancer.Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours Emerging treatment options for management of malignant ascites in patients with ovarian cancer.A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report Anti-angiogenic treatment of gastrointestinal malignancies.Contrasting effects of sunitinib within in vivo models of metastasis.Correlated magnetic resonance imaging and ultramicroscopy (MR-UM) is a tool kit to assess the dynamics of glioma angiogenesis.Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation

P2860

Q24548357-0F960D7B-BD4F-4BE2-86BC-CFD0D642B409 Q24600199-33B14EB1-4911-44BC-A30A-51E53C8612CD Q28478248-6A8DF9E3-7BB5-4243-881A-C4A755B95B5F Q28575249-1070814A-23A0-4262-BB7F-FB76D1B8421A Q30409780-4E275260-D6D8-4DCD-8AB2-AF544EB8BA40 Q30424925-C4596CF1-D85E-416D-905C-F208D5D62FCE Q30454165-6DD6C1CA-E873-400F-A528-1B9FDB9C3C5D Q30455612-10A2F57B-81D1-4155-B5E3-B8674895D41B Q30539500-B0D0DF10-0AEB-47FA-BC7F-96A8D825699D Q30572671-6D43CA46-4227-4D40-B1D6-3225E2492F47 Q33215197-C609D638-9E2C-4952-A477-BC8EC97C593B Q33520467-AAFBE4D3-3302-4EE8-86F3-A4C9F79DC643 Q33709909-E0799A5D-6024-4766-87C0-81DA83F279A1 Q33732486-09D57455-5B0B-4940-97F6-F148991918E9 Q33733437-52A54E5F-165E-45EA-BC10-9A5ED363C48F Q34382777-D0B0A798-F179-4C95-94F6-61E9E55CF9E1 Q34413488-276FAD1B-DD02-454C-806B-CD3273B79389 Q34414237-A237D5E0-AAA6-4144-AC11-6305408A8F95 Q34515465-A7C8EFDA-C033-437C-BEEB-4577292AE281 Q35018356-1D0B3BF6-7489-41BE-AA6E-EE079AF331AC Q35052385-070C153A-CB75-45BB-9534-F8ED5ADB0CB0 Q35084870-D895FF78-1313-4460-9A90-EF9EAFBB9687 Q35102889-F0C002CD-317D-40BD-9EF6-6DD0238ED31D Q35109936-DC3E2280-A20C-4BE6-A53A-4413574B8CF4 Q35170252-1CDB7D02-50D1-452A-9482-1C03CF93C656 Q35178731-12D33E0E-D2EC-4636-8C58-BE3245806190 Q35413008-2D54FE5E-B136-4FEE-B459-3F3DDC31C574 Q35599819-5740F271-5045-408D-BE99-97A4688238E9 Q35904985-2ED2552D-BDF5-4F62-932F-BFD849ABB214 Q36051383-AA920E19-673F-42E4-83B2-43C5674AF7A4 Q36150646-F900F31D-1363-4129-B2B4-29F6E4C97D97 Q36158717-5121863B-84B2-4008-A9BE-8D81A321FB3B Q36166808-E8CBB2C5-0D54-4EAB-A377-C2E63D29F718 Q36173084-DA9D2CAC-6D69-4964-BE7B-41173C0D3BB1 Q36243701-5E39CC7E-02A1-4427-91E7-F423BB37F027 Q36353516-865533EC-3D8C-4F7D-AC1D-390E41914FD3 Q36394262-0844C0E3-509A-4C33-95A6-09F5E87868C2 Q36585924-9466DEA6-DE27-43F2-90DC-8BAF232D27DF Q36665931-598D068E-1DB0-4A89-9C09-E45E7CFFC938 Q36891571-D892CBD8-A0C2-48D8-ABA9-9CF32C24BF14

P2860

Regression of established tumors and metastases by potent vascular endothelial growth factor blockade.

http://www.wikidata.org/entity/Q35146833

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Regression of established tumo ...... helial growth factor blockade.

@ast

Regression of established tumo ...... helial growth factor blockade.

@en

type

label

Regression of established tumo ...... helial growth factor blockade.

@ast

Regression of established tumo ...... helial growth factor blockade.

@en

prefLabel

Regression of established tumo ...... helial growth factor blockade.

@ast

Regression of established tumo ...... helial growth factor blockade.

@en

P1433

Q35146833-88D682CA-2C37-45CA-BAEE-414A320220A5

P1476

Q35146833-70F12C74-DDE4-4151-B4C3-E7CDD9A82793

P2093

Q35146833-0C8E165B-B39E-4C9C-82A6-FBBB8C7D071F

Q35146833-4375E50F-F6B2-43B7-BFA5-0FB1532042F5

Q35146833-46F79B10-C89E-4F02-AA5B-4F8EC1422B75

Q35146833-55BE709B-2A03-4B98-A6A9-72BB74296516

Q35146833-5E1FBE0A-116E-4F78-BD86-BFF9A2602C32

Q35146833-6759DB56-E8C0-499E-9C7B-099439E576E2

Q35146833-69D77BF0-E339-48EE-B8FD-B0BDE9F7370D

Q35146833-99930912-CB2A-43DB-86BC-7ACADCE53676

Q35146833-A44974F4-B731-45EA-9CB5-CFC1E5D4436E

Q35146833-A81BA0B7-626F-4B66-A10F-3B6AB365D3A4

P2860

Q35146833-0BB60435-4B44-4B57-8FC2-FC8E994EDE42

Q35146833-296437FB-AF1F-493D-BD74-9CB0E53BDEF1

Q35146833-43586330-5B49-4450-99D7-1B6C39D0C7A5

Q35146833-49EE466C-7F81-4D04-AB0A-B0F71EB01613

Q35146833-4AEA8A18-9DB3-4EF4-B731-6F024EE378D1

Q35146833-54752B36-99F8-49EF-A79A-7BFD4C3D0C0B

Q35146833-572B1BF5-3D07-462C-AF86-9E2E9CB64F53

Q35146833-58F4CAE0-F8B6-46B7-AF6B-7D83743FCCB5

Q35146833-7354766F-6EFE-41F9-A1C6-CA48E9371DE3

Q35146833-77419115-DCC2-4A01-8AC9-DEF232B5DB5B

P304

Q35146833-D99441A4-0429-4EC5-B3A5-37F0ABFF7F44

P31

Q35146833-AAA65C17-BBD1-4B6D-AF21-23C11F23E8B3

P356

Q35146833-AA65362B-A7F7-4C20-AE72-9F30E340F908

P407

Q35146833-5C885091-0506-4115-BD9E-7522686EAC1E

P433

Q35146833-40502677-7635-4C89-A986-9E30FCC4B4AB

P478

Q35146833-15009EC4-CC82-49EE-9BCE-C975C1AD3710

P577

Q35146833-0B700370-E58E-4073-9D9C-D4EE0351F874

P5875

Q35146833-2C5CB208-7FEE-49D7-A8A3-1BA7E3C88BB6

P698

Q35146833-11218392-61FA-4BFA-8B9C-ED23C007A4A0

P921

Q35146833-46C5F4DC-71A6-41C0-9B95-168F342B7FF2

P932

Q35146833-E6DF5A0B-E31D-4F1A-B831-33FF4F1DA59A

P356

PNAS.1432908100

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Regression of established tumo ...... helial growth factor blockade.

@en

P2093

Akiko Yokoi

http://www.w3.org/2001/XMLSchema#string

Angela Kadenhe

http://www.w3.org/2001/XMLSchema#string

Anna Serur

http://www.w3.org/2001/XMLSchema#string

Darrell J Yamashiro

http://www.w3.org/2001/XMLSchema#string

George D Yancopoulos

http://www.w3.org/2001/XMLSchema#string

Jason S Frischer

http://www.w3.org/2001/XMLSchema#string

Jessica J Kandel

http://www.w3.org/2001/XMLSchema#string

Jianzhong Huang

http://www.w3.org/2001/XMLSchema#string

Jocelyn Holash

http://www.w3.org/2001/XMLSchema#string

John S Rudge

http://www.w3.org/2001/XMLSchema#string

P2860

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density.

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.

Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer.

Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors

Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.

P304

7785-7790

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1432908100

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P577

2003-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6985258

http://www.w3.org/2001/XMLSchema#string

P698

12805568

http://www.w3.org/2001/XMLSchema#string

P921

P932

164665

http://www.w3.org/2001/XMLSchema#string